Procter & Gamble's Jon Moeller joins the Lilly board; Karen Walker resigns

Eli Lilly announced on Nov. 19, 2024, that it elected Jon Moeller, chairman, president and chief executive officer of Procter & Gamble, to its board of directors, effective Dec. 1, 2024 ^[1]. At the same time, the company said director Karen Walker will resign from the board effective Dec. 31, 2024, and instead work with Lilly in 2025 on certain digital commercial activities ^[1].

Moeller will sit on Lilly's Audit Committee and its Directors and Corporate Governance Committee ^[1]. He has spent more than two decades at P&G, including stints as vice chairman, chief financial officer and chief operating officer, where he oversaw the company's developing markets and global operations ^[1]. He also serves on the boards of the Business Roundtable, the Consumer Goods Forum, and Catalyst, a nonprofit focused on workplace inclusion for women ^[1]. Lilly said Moeller will stand for election by shareholders at the company's annual meeting in May 2026 ^[1].

Walker has served on Lilly's board since 2018, sitting on the Audit and Talent and Compensation Committees ^[1]. Before joining Lilly's board, she was an operating partner with The Goldman Sachs Group and served as chief marketing officer at both Intel Corporation and Cisco Systems ^[1]. Lilly credited her with bringing expertise in brand-building, go-to-market strategy and technology to the board during what the company called a period of significant growth ^[1]. Lilly chair and CEO David A. Ricks said the board is "grateful that she will continue to contribute to Lilly's growth as we scale our digital and commercial capabilities" ^[1].

The announcement, filed with the Securities and Exchange Commission, does not specify the nature of the digital commercial work Walker will do for Lilly in 2025, nor does it detail compensation for that arrangement ^[1].

Why it matters for patients

This is a governance and leadership change at the corporate level, not a change to any Lilly product. It does not affect the availability, price, or approved use of Mounjaro or Zepbound (tirzepatide), and the announcement makes no mention of clinical trials, manufacturing, or drug safety ^[1]. Board appointments like this typically signal how a company plans to manage its business strategy and oversight rather than anything that changes what patients experience with a medication.

Still, patients who follow Lilly as a company may notice the shift because it points to where the company is focusing outside expertise. Moeller's background is in large-scale consumer operations and finance at P&G, an